Drugs Made In America Acquisition Corp. DMAA
10.84
(0.01)
(0.09%)
as of 25 Sep
- Market cap
- $263.4M
- P/E
- —
Follow DMAA
Target Price Range
Analyst price targets
Free account| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | 9.95 | 10.37 |
Analyst estimates 2027–2029 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | 10.37 | 10.86 |
High Price
|
|||
| — | — | — | — | — | — | — | — | — | — | Employees | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Emp | |||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | — | — | EBT | |||
| — | — | — | — | — | — | — | — | — | — | EBT Margin | |||
| — | — | — | — | — | — | — | — | — | — | Net Income | |||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Earnings/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Cash Flow/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Capex/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Free CF/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Book Value/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Shares | |||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | — | — | Op' Cash Flow | |||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | — | — | FCF | |||
| — | — | — | — | — | — | — | — | — | — | Working Cap' | |||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | — | — | Net Debt | |||
| — | — | — | — | — | — | — | — | — | — | Sh' Equity | |||
| — | — | — | — | — | — | — | — | — | — | ROA | |||
| — | — | — | — | — | — | — | — | — | — | ROIC | |||
| — | — | — | — | — | — | — | — | — | — | ROE | |||
predictions in italic, sparklines do not include predictions
Drugs Made In America Acquisition Corp. peers in Shell Companies
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| OACC Oaktree Acquisition Corp. III Life Sciences | $265.0M | — | Compare |
| DNMX Dynamix Corporation III | $269.7M | — | Compare |
| RAC Rithm Acquisition Corp. | $256.0M | — | Compare |
| SOUL Soulpower Acquisition Corporation | $271.6M | — | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CEPO Cantor Equity Partners, Inc. | $274.5M | 0.0× | Compare |
| PAII Pyrophyte Acquisition Corp. II | $280.9M | — | Compare |
| AXIN Axiom Intelligence Acquisition Corp 1 | $281.9M | — | Compare |
| MCGA Yorkville Acquisition Corp. | $244.3M | — | Compare |
Drugs Made In America Acquisition Corp. (DMAA) Latest News
16 Aug
Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) is definitely on the radar of institutional investors who own 38% of the company
Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) has garnered attention from institutional investors, who collectively own 38% of the company. This significant ownership stake indicates a growing interest in DMAA's potential within the market, suggesting that institutional players are optimistic about its future prospects. Institutional ownership at 38% reflects moderate confidence in DMAA's future performance and market positioning.